No Credit Check Payday Loans
ALL BOOKS
Seeds

Pharmacology

Substances
Overdose

JoomlaWatch Agent

Visitors hit counter, stats, email report, location on a map, SEO for Joomla, Wordpress, Drupal, Magento and Prestashop

JoomlaWatch Users

JoomlaWatch Visitors



54% United States  United States
11.2% United Kingdom  United Kingdom
5.9% Australia  Australia
5.6% Canada  Canada
3.3% Philippines  Philippines
2.2% Kuwait  Kuwait
2.1% India  India
1.6% Germany  Germany
1.5% Netherlands  Netherlands
1.1% France  France

Today: 174
Yesterday: 310
This Week: 1537
Last Week: 2303
This Month: 5349
Last Month: 5638
Total: 24114


6. Conclusions PDF Print E-mail
User Rating: / 0
PoorBest 
Reports - EMCDDA Report on the risk assessment of Ketamine
Written by Richard Dennis   

The Scientific Committee of the EMCDDA, enlarged with experts from the
Member States and representatives of the Commission, Europol and EMEA,
have considered the health and social risks as well as the possible consequences
of prohibition of ketamine and, in accordance with Article 4 of the
joint action, submit the following conclusions:

6.1. Ketamine is not a new synthetic drug. While it has a significant
therapeutic use, it is also being used in recreational settings.

6.2. The meeting noted the main risks of the recreational use of the drug,
such as psychological dependence, loss of self-control and the risk of
acute intoxication. To date, the use of ketamine has been reported as
associated with mortality or morbidity in a small number of cases.

6.3. An opinion which received strong support at the meeting was that,
as a common minimum, ketamine should be subject to control under
medicines legislation in Member States.

6.4. Another strong opinion expressed at the meeting was that, in addition
to the medicines legislation, stronger control measures to deal with
diversion, trafficking and inadvertent exposure to the drug were necessary.

6.5. The meeting recommends that both the EMCDDA and Europol should
further monitor the manufacture, trafficking, distribution, patterns of use
and health consequences of ketamine, particularly the fatalities and
non-fatal emergencies.

6.6. The meeting recommends that a study on the possible neurotoxicity of
ketamine in primates should be considered in the context of the fifth
framework research programme of the European Commission.

6.7. The possible options for improving control of diversion should be
discussed with the chemical and pharmaceutical industry in order to
ensure the continued availability of ketamine for medical and veterinary
use.

6.8. The meeting recommends that consideration should be given to how
appropriate information can be disseminated to the most vulnerable risk
groups.

Lisbon, 25 September 2000

 

Our valuable member Richard Dennis has been with us since Monday, 20 February 2012.

Show Other Articles Of This Author